DepressionTRDNovember 13, 2026
A First for Treatment-Resistant Depression: Esketamine Approved as a Stand-Alone Therapy
In January 2025 the FDA approved Spravato (esketamine) nasal spray for use on its own in adults with treatment-resistant depression. Here is what changed and what the trial showed.
